Health/Disease Strategy

With influenza activity increasing sharply, here’s how healthcare executives can determine which health plan members are at risk for the flu.

Catherine Bollard, MD, discusses the success rate of CAR T-cell treatments, remaining obstacles, and top payer considerations.

More targeted therapies for autoimmune diseases are on the horizon. Here’s what to anticipate in 2018.

With the right preventions in place, hospitals and healthcare executives will be well positioned to respond to these four risks in 2018.

A new survey has eye-opening findings about the status quo one-size-fits-all health plan.

Fifty percent of Americans have high blood pressure, per new guidelines. Here’s how those guidelines could affect medication utilization and healthcare spending.

Successful community initiatives are creating systems of care that bridge multiple programs to provide coordinated services to individuals with substance use disorders. Here are five.

Here’s your quick guide to understanding how CAR T-cell therapy could affect patients and payers.

A new report from Cardinal Health Specialty Solutions gives behind-the-scenes perspectives from oncologists about CAR-T cell therapies, biosimilars and AML therapies (or genomic medicines)

Simple strategies can improve the nutritional well-being of COPD patients and help them maintain their weight.

Prepare for major pipeline developments in diabetes, autoimmune disorders, oncology, and COPD.

The Innovation and Value Initiative launched the Open-Source Value Project, creating tools that help payers, providers, and healthcare systems make informed and patient-centered decisions that produce better health outcomes.

Two new studies address the financial implications of unexpected major healthcare expenses for common cardiovascular conditions and procedures.

While CAR T-cell therapy has been proven to work for liquid-or blood-cancers, the challenge has been to apply this technology to solid tumors.

A poll from the Biosimilars Council, a division of the Association for Accessible Medicines, has interesting findings about placing biosimilars and branded biologics on a level playing field to save money.

Transplant eligibility issues and drug regimen options raise difficult questions when treating older multiple myeloma patients.

Treating RA is a work in progress. Here’s what you need to know.

Howard Shaps, MD, senior medical director, WellCare of Kentucky, shares details about the Medicaid insurers’ pilot program designed to fight the opioid epidemic.

Here are six healthcare impact trends that will challenge marketers in the upcoming year.

Autologous stem cell therapy may offer hope for patients with COPD. But some say caution is necessary.

A new study led by UCLA researchers has eye-opening findings about low-cost, high-volume unnecessary healthcare. These low-value services may surprise you.

A new study has shocking findings about death rates in heart failure patients enrolled in the Hospital Readmissions Reduction Program.

CAR T-cell therapies and other immunotherapy give this oncologist’s cancer patients hope for a better quality of life.

Two patient survey studies sponsored by Mallinckrodt reveal findings about patient-reported multiple sclerosis rates.

Allergist Bradley Chipps, MD, shares research on how to fine-tune asthma management strategies.

A Canadian study reveals how clinicians may be able to identify whether asthma will develop in patients as young as age one.

Experts say a cancer care revolution is here. Here’s a closer look at some advancements in cancer treatments to watch.

A new survey on genetic testing has surprisingly results on consumer acceptance and impact for healthcare executives.

A Kaiser Permanente study found that a new way to test for HPV has the potential to increase efficiency and decrease waste.

Albert A. Rizzo, MD, senior medical advisor for the American Lung Association, says the increasing number of drugs in the pipeline could improve airflow and address the underlying disease process.